Table 11.
Targeted Therapy in ACC (All Advanced Disease/Failed Therapy)
| Study | Year | Regimen | Disease | Total Number | CR | PR | SD | %CR, PR | %CR, PR, SD | Response Duration, mo |
|---|---|---|---|---|---|---|---|---|---|---|
| Rustin (388) | 2003 | Combretastatin | Advanced/failed | 1 | 0 | 1 | 0 | 100 | 100 | Continued after initial PD |
| Shah (389) | 2005 | Irinotecan, flavopiridol, CDK inhibitor | Advanced/failed | 2 | 0 | 0 | 2 | 0 | 100 | 8.1–15.4 |
| Gross (390) | 2006 | Imatinib | Advanced/failed | 4 | 0 | 0 | 0 | 0 | 0 | NA |
| Quinkler (391) | 2008 | Erlotinib, gemcitabine | Advanced/failed | 10 | 0 | 0 | 1 | 0 | 10 | 8 |
| Hong (392) | 2009 | Sorafenib, tipifarnib | Advanced/failed | 2 | 0 | 0 | 2 | 0 | 100 | 4 and 7 |
| Wortmann (239) | 2010 | Bevacizumab, gemcitabine | Advanced/failed | 10 | 0 | 0 | 0 | 0 | 0 | |
| Haluska (316) | 2010 | Figitimumab | Advanced/failed | 14 | 0 | 0 | 8 | 0 | 57 | 3–5.5 |
| Naing (317) | 2011 | Cixutumab, temserolimus | Advanced/failed | 10 | 0 | 0 | 4 | 0 | 40 | 8+ |
| Berruti (393) | 2012 | paclitaxel, sorafenib | Advanced/failed | 25 | 0 | 0 | 0 | 0 | 0 | Progression in 9 patients, early termination |
| Kroiss (304) | 2012 | Sunitinib | Advanced/failed | 35 | 0 | 0 | 5 | 0 | 14 | 5.6–11.2 |
| Total | 113 | 0 | 1 | 22 | 1 | 20 | ||||
| Median | 0 | 27 |
Abbreviations: PR, partial remission; SD, stable disease; CR, complete remission; mo, months.